ARB类药物治疗原发性高血压的药物经济学研究

目的:对血管紧张素II受体阻滞剂(ARB)类药物治疗原发性高血压的经济学评价文献进行归纳分析,并提出合理的用药指导方案.方法:检索中国知网、万方及PubMed等中英文数据库,对2006—2015年ARB类药物治疗原发性高血压的经济学评价文献进行分析及总结.结果:9组给药方案中有7组包含厄贝沙坦,总有效率分别为72.7％...

Pharmacoeconomic Study of ARB Drugs in the Treatment of Essential Hypertension

Objective:To summarize and analyze the literature on the economic evaluation of angiotensin II receptor blockers(ARB)in the treatment of essential hypertension,and put forward the reasonable medication guidance scheme.Methods:Chinese and English databases such as CNKI,Wanfang and PubMed were searched to analyze and summarize the literature on the economic evaluation of ARB drugs in the treatment of essential hypertension from 2006 to 2015.Results:The total effective rates were 72.7%、93%、83%、72.7%、83.3%、83.3%and 80.6%respectively,and the C/E were 2.33、2.2、7.91、2.21、7.91、7.91 and 7.93 respectively.The results of minimum cost analysis andΔC/ΔE ratio calculation in two groups showed that irbesartan had the lowest cost andΔC/ΔEratio.The results of univariate sensitivity analysis showed that irbesartan was more cost-effective in three groups.Conclusion:Irbesartan is an ARB drug with better cost-effectiveness and less adverse reactions in the treatment of patients with essential hypertension.However,the scope of domestic cost analysis is too single,and the variables of sensitivity analysis are too few,so the research results need further analysis.